Previous close | 0.5000 |
Open | 0.5000 |
Bid | 0.0000 |
Ask | 0.6500 |
Strike | 2.50 |
Expiry date | 2024-06-21 |
Day's range | 0.5000 - 0.5000 |
Contract range | N/A |
Volume | |
Open interest | 343 |
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomi
Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. Revenue crushed...
Compugen (CGEN) delivered earnings and revenue surprises of 20% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?